Ginsenoside ompound K reduces neuronal damage and improves neuronal synaptic dysfunction by targeting Aβ.

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by amyloid-beta (Aβ) fibril accumulation.
• Synaptic damage and cognitive impairment are key pathological features of AD.
• Ginsenoside Compound K (CK) is investigated for its potential therapeutic effects.

Purpose of the Study:

• To investigate the activity of Ginsenoside Compound K (CK) against amyloid-beta (Aβ) aggregation.
• To elucidate the mechanism by which CK reduces synaptic damage and cognitive impairment.
• To evaluate CK's therapeutic efficacy in an Alzheimer's disease mouse model.

Main Methods:

• Molecular docking to assess CK binding to Aβ42 and Nrf2/Keap1.
• Transmission electron microscopy for monitoring Aβ fibril degradation.
• Cell viability assays (CCK-8), cognitive tests (step-down passive avoidance), and molecular analyses (western blotting, immunofluorescence, Genechip) were employed.

Main Results:

• CK demonstrated binding to Aβ42 and reduced Aβ aggregation, while increasing insulin-degrading enzyme and decreasing β-secretase and γ-secretase levels.
• CK treatment improved cognitive function, increased synaptic protein expression (postsynaptic density protein 95, synaptophysin), and reduced neuronal apoptosis markers (cytochrome C, Caspase-3).
• CK modulated the Nrf2/Keap1 signaling pathway, enhanced antioxidant activity, and regulated genes involved in oxygen binding and oxidoreductase activity.

Conclusions:

• Ginsenoside Compound K (CK) effectively inhibits amyloid-beta (Aβ) accumulation by binding to monomers and promoting clearance.
• CK protects neurons by reducing oxidative stress, enhancing synaptic function, and activating the Nrf2 pathway.
• CK shows significant therapeutic potential for Alzheimer's disease by addressing key pathological mechanisms.